Teladoc Health Statistics
Total Valuation
Teladoc Health has a market cap or net worth of $1.20 billion. The enterprise value is $1.60 billion.
Important Dates
The next estimated earnings date is Wednesday, July 30, 2025, after market close.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Teladoc Health has 175.43 million shares outstanding. The number of shares has increased by 3.85% in one year.
| Current Share Class | 175.43M |
| Shares Outstanding | 175.43M |
| Shares Change (YoY) | +3.85% |
| Shares Change (QoQ) | +0.80% |
| Owned by Insiders (%) | 1.09% |
| Owned by Institutions (%) | 67.71% |
| Float | 164.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.46 |
| Forward PS | 0.47 |
| PB Ratio | 0.84 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 4.17 |
| P/OCF Ratio | 4.00 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 48.66, with an EV/FCF ratio of 5.54.
| EV / Earnings | n/a |
| EV / Sales | 0.63 |
| EV / EBITDA | 48.66 |
| EV / EBIT | n/a |
| EV / FCF | 5.54 |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 1.11.
| Current Ratio | 1.68 |
| Quick Ratio | 1.51 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | 34.85 |
| Debt / FCF | 5.50 |
| Interest Coverage | -7.80 |
Financial Efficiency
Return on equity (ROE) is -54.49% and return on invested capital (ROIC) is -3.38%.
| Return on Equity (ROE) | -54.49% |
| Return on Assets (ROA) | -3.00% |
| Return on Invested Capital (ROIC) | -3.38% |
| Return on Capital Employed (ROCE) | -7.49% |
| Revenue Per Employee | $464,148 |
| Profits Per Employee | -$184,067 |
| Employee Count | 5,500 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 21.44 |
Taxes
| Income Tax | -13.35M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.75% in the last 52 weeks. The beta is 1.78, so Teladoc Health's price volatility has been higher than the market average.
| Beta (5Y) | 1.78 |
| 52-Week Price Change | -32.75% |
| 50-Day Moving Average | 7.14 |
| 200-Day Moving Average | 8.95 |
| Relative Strength Index (RSI) | 42.44 |
| Average Volume (20 Days) | 4,640,006 |
Short Selling Information
The latest short interest is 23.05 million, so 13.14% of the outstanding shares have been sold short.
| Short Interest | 23.05M |
| Short Previous Month | 20.90M |
| Short % of Shares Out | 13.14% |
| Short % of Float | 14.00% |
| Short Ratio (days to cover) | 4.29 |
Income Statement
In the last 12 months, Teladoc Health had revenue of $2.55 billion and -$1.01 billion in losses. Loss per share was -$5.88.
| Revenue | 2.55B |
| Gross Profit | 1.80B |
| Operating Income | -186.65M |
| Pretax Income | -997.92M |
| Net Income | -1.01B |
| EBITDA | 32.82M |
| EBIT | -186.65M |
| Loss Per Share | -$5.88 |
Full Income StatementBalance Sheet
The company has $1.19 billion in cash and $1.59 billion in debt, giving a net cash position of -$393.44 million or -$2.24 per share.
| Cash & Cash Equivalents | 1.19B |
| Total Debt | 1.59B |
| Net Cash | -393.44M |
| Net Cash Per Share | -$2.24 |
| Equity (Book Value) | 1.43B |
| Book Value Per Share | 8.14 |
| Working Capital | 649.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $300.68 million and capital expenditures -$12.37 million, giving a free cash flow of $288.31 million.
| Operating Cash Flow | 300.68M |
| Capital Expenditures | -12.37M |
| Free Cash Flow | 288.31M |
| FCF Per Share | $1.64 |
Full Cash Flow StatementMargins
Gross margin is 70.48%, with operating and profit margins of -7.31% and -39.66%.
| Gross Margin | 70.48% |
| Operating Margin | -7.31% |
| Pretax Margin | -40.18% |
| Profit Margin | -39.66% |
| EBITDA Margin | 1.29% |
| EBIT Margin | -7.31% |
| FCF Margin | 11.29% |
Dividends & Yields
Teladoc Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.85% |
| Shareholder Yield | -3.85% |
| Earnings Yield | -84.12% |
| FCF Yield | 23.96% |
Dividend DetailsAnalyst Forecast
The average price target for Teladoc Health is $9.60, which is 39.94% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.60 |
| Price Target Difference | 39.94% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 2.50% |
| EPS Growth Forecast (5Y) | -32.11% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Teladoc Health has an Altman Z-Score of -5.33 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.33 |
| Piotroski F-Score | 4 |